Opdivo Improves Survival in Advanced Esophageal Cancer: ATTRACTION-3 Trial
Medical Supporter — Мэдээллийн мэдэгдэл
Энэ нийтлэл нь олон улсын эмнэлгийн мэдээллийн эмхэтгэл бөгөөд эмнэлгийн зөвлөгөө биш; таны эмчийн оношлогоо, эмчилгээний төлөвлөгөөг орлохгүй. Энд буй мэдээлэл нь Японы томоохон эмнэлгийн байгууллагуудын нээлттэй эх сурвалжаас эмхэтгэсэн бөгөөд аливаа эмчилгээний тохиромж, үр дүн өвчтөн бүрээр өөр тул мэргэшсэн эмч тус бүрчлэн үнэлэх ёстой.
On September 30, 2019, clinical results were announced for the ATTRACTION-3 Phase 3 clinical trial, evaluating the anti-PD-1 antibody Opdivo (Nivolumab) in patients with unresectable advanced or recurrent esophageal cancer who were refractory to or intolerant of fluoropyrimidine- and platinum-based chemotherapy.
Study Design: ATTRACTION-3 Trial
This international, multicenter, open-label trial randomized patients into two groups:
- Opdivo Group: Nivolumab monotherapy.
- Chemotherapy Group: Investigator's choice of Taxotere (docetaxel) or Paclitaxel.
The primary endpoint was overall survival (OS).
Key Survival Results
The trial demonstrated a significant survival benefit for Opdivo:
- Median Overall Survival: 10.9 months for Opdivo vs. 8.4 months for chemotherapy.
- Risk Reduction: Opdivo reduced the risk of death by 23% (Hazard Ratio [HR] = 0.77).
- 12-Month OS Rate: 47% (Opdivo) vs. 31% (Chemotherapy).
- 18-Month OS Rate: 31% (Opdivo) vs. 21% (Chemotherapy).
Importantly, the survival benefit of Opdivo was observed regardless of the patient's PD-L1 expression levels.
Efficacy and Safety
- Objective Response Rate (ORR): 19% for Opdivo vs. 22% for chemotherapy.
- Duration of Response: Significantly longer with Opdivo (6.9 months) compared to chemotherapy (3.9 months).
- Safety: Opdivo was better tolerated, with a Grade 3/4 adverse event rate of 18% compared to 63% in the chemotherapy group.
Conclusion
Dr. Byoung Chul Cho and colleagues concluded that Opdivo significantly improves overall survival compared to standard chemotherapy in patients with previously treated advanced esophageal cancer, with a more favorable safety profile. These results support Opdivo as a new second-line standard of care for this population.
Source: BMS Press Release - ATTRACTION-3 Trial Results
#EsophagealCancer #Opdivo #Nivolumab #ATTRACTION3 #Immunotherapy #CancerResearch
Японд эмчлүүлэхээр төлөвлөж байна уу? Мэдээлэл, тусламж хэрэгтэй юу?
Бид Японд эмчлүүлэхэд шаардлагатай мэдээллийг эмхэтгэх, Японы эмнэлгийн байгууллагуудтай холбогдох, хоёр дахь саналын зөвлөгөө зохион байгуулахад тусална.Анхны зөвлөгөө үнэгүй; зөвлөх таны дараагийн алхмыг тодорхой болгоход тусална.
Figure 1
Figure 2
Figure 3
Figure 4